Introduction
Although the spectra of activities within the macrolide, streptogramin and lincosamide (MLS) groups are similar, [1] [2] [3] [4] the in-vitro evaluation of the MLS antibiotics has encountered some common problems. 4, 5 The increasing frequency of methicillin-resistant Staphylococcus aureus (MRSA) and their frequently reported unpredictable susceptibility to antimicrobial agents underlines the need for in-vitro testing of these organisms. 5 In addition, for some of the newer macrolides the MICs may have to be related to tissue rather than to blood concentrations of the antibiotic. 6, 7 In contrast to the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS), 8 almost no reference data are available on the application of susceptibility testing methods according to the Deutsches Institut für Normung (DIN) 58940 for macrolides and lincosamides. [9] [10] [11] Breakpoints are given by DIN 58940 only for erythromycin and clindamycin. 12 Therefore, the in-vitro activities of erythromycin, josamycin, azithromycin, roxithromycin, clarithromycin (all macrolides) and clindamycin (a lincosamide) were determined for 674 clinical isolates, including 387 Gram-positive strains (with 295 staphylococci, of which 152 were oxacillinresistant). Their susceptibilities were determined by microdilution, agar dilution and agar diffusion according to the DIN 58940 guidelines.
Materials and methods

Bacterial strains
Three hundred and ninety-six Gram-positive and 248 Gram-negative strains of 13 genera, including 140 Haemophilus and 152 methicillin-resistant strains from two university hospitals in Munich, Germany (Technical University and Ludwig-Maximilian University), the laboratory of Dr Gärtner (Weingarten, Germany) and the German National Staphylococcal Reference Centre (RKI, Wernigerode, Germany) were included in this study (the number of strains tested is given in brackets): Acinetobacter anitratus (6) 
Antimicrobial agents
Pure azithromycin was obtained from Pfizer Inc. (Groton, CT, USA), roxithromycin was obtained from Roussell Uclaf (Romainville, France), clarithromycin from Abbott GmbH (Wiesbaden, Germany), erythromycin, lincomycin and midekamycin from Sigma (Munich, Germany). The antimicrobial agents were dissolved in 2 mL of methanol and diluted further with distilled water. Two-fold serial dilutions of the antibiotic powder were freshly prepared with 0.01 M phosphate buffer, pH 7.4, with either Mueller-Hinton or Iso-Sensitest medium. All dilutions and inocula were prepared with an automatic pipetting system (MICRO-AT Plus, Hamilton, Switzerland). When this study was performed, azithromycin and roxithromycin discs were not commercially available, so test discs (azithromycin 15 g and roxithromycin 15 g; 6 mm diameter) were manufactured in our laboratory. Erythromycin (15 and 30 g), clindamycin (15 g ) and josamycin (30 g) discs were obtained from Oxoid/ Unipath (Wesel, Germany); test tablets for clarithromycin were purchased from ROSCO (Taastrup, Denmark). The antimicrobial load on the discs/tablets was checked by the bioassay method according to DIN 58940 part 2. 13 The discs performed identically to commercially available discs and their antimicrobial activity was not reduced after 1 year of refrigeration.
Susceptibility testing
MICs were determined by the broth microdilution and the agar dilution method according to the DIN 58940 guidelines. 10, 11 Inhibition zone diameters (IZD) were determined with a video image analysis system (Omnicon 3600, Biosys GmbH, Karben, Germany) when performing the disc diffusion method according to the DIN 58940 guidelines. 9 Agar diffusion was carried out in 150 mm diameter Petri dishes with a culture medium depth of 4 mm. The surface of the medium was inoculated using a cotton swab by means of three consecutive and overlapping cross-streaks; the inoculum was 1 10 6 cfu/mL. The inoculum for agar dilution was transferred using a multipoint inoculator (Denley Ltd, UK) to the surface of the medium (1 10 4 to maximum 4 10 4 cfu/spot). The microdilution wells containing culture medium and antimicrobial agents (10 L solution of twice the required final concentration of antibiotic) were inoculated with 100 L of the bacterial suspension (2 10 4 -5 10 4 cfu/mL). Agar diffusion, agar and broth microdilution tests were incubated for 16-18 h in ambient air at 36°C 1°C; disc tests with haemophilus were incubated at 36°C 1°C in 4-5% CO 2 atmosphere.
Methicillin resistance
Methicillin resistance was assessed by the oxacillin-salt agar screening test, recommended by the NCCLS. 14 
Culture media
The same lots of Mueller-Hinton and Iso-Sensitest medium (Unipath/Oxoid) were used for all tests. For testing Haemophilus species modifications to the culture media were applied as reported for the haemophilus test medium by Doern et al.
16
-Lactamase determination -Lactamase activity was determined with the nitrocefin chromogenic cephalosporin test (Becton Dickinson GmbH, Heidelberg, Germany).
Statistical evaluation
The MIC and IZD data were tabulated and evaluated by regression and Metzler-DeHaan analysis 15 and by correlation analysis, using the SAS software package (SAS Institute, Cary, NC, USA). The error-rate-bounded Metzler-DeHaan method was optimized for the personal computer application.
Results
The MIC distribution of the antibiotics tested by microdilution testing with Mueller-Hinton medium for the Gram-positive and Gram-negative collection, including S. aureus and Haemophilus spp. is shown in Table I . Mueller-Hinton and Iso-Sensitest media gave similar MIC distributions; only the results of the former are shown. The distribution of IZDs for azithromycin, roxithromycin, erythromycin and josamycin are given in Figure 1 .
When MICs obtained by the agar dilution and microdilution methods were compared only minor differences were seen; these did not exceed two dilution steps. The same was true of IZDs: differences between the two media were in the range of 5 mm (data not shown).
When Gram-positive clinical isolates were compared for their susceptibility to the macrolide/lincosamide antibiotics, a MIC of 8 mg/L was obtained for approximately 80% of the strains with josamycin, midekamycin and lincomycin, for 60% of strains with azithromycin, roxithromycin and erythromycin, and for only 48% of strains with clarithromycin (Table I) . When roxithromycin, josamycin, erythromycin and azithromycin were tested against Haemophilus spp., MICs of 8 mg/L were shown for 61%, 84%, 98% and 100% of strains, respectively.
Of the oxacillin-resistant staphylococci (Table II) up to 60% were susceptible to josamycin, midekamycin and clindamycin, and about 23% susceptible to azithromycin, roxithromycin, clarithromycin and erythromycin. Erythromycin-resistant strains (Table II) also showed resistance to roxithromycin, clarithromycin and azithromycin, whereas about 45-50% of these were still susceptible to josamycin, midekamycin and clindamycin. Up to 80% of S. haemolyticus strains were susceptible to josamycin, midekamycin and clindamycin (Table II) . Table III shows the breakpoints calculated by regression analysis according to DIN 58940, 13 the correlation coefficients and constants a and b from the appropriate regression equation, and the values from the error-rate-bounded analysis method according to Metzler-DeHaan (MEDHA). 15 For breakpoint calculation, strains with an MIC of 2 mg/L were considered susceptible to macrolides, and strains with a MIC of 8 mg/L resistant.
Although the correlation coefficients were often very similar, the calculated error rates demonstrated important differences in the ability to predict appropriate MIC categories. Very similar results were obtained for MuellerHinton and Iso-Sensitest medium (data not shown) and unique IZD breakpoints may therefore be suggested for both culture media (Table IV) . Figure 2 shows the scatterplot with regression line for S. aureus and the macrolides erythromycin, josamycin, azithromycin and roxithromycin.
Discussion
The in-vitro susceptibility testing performed in accordance with the methods described in the DIN 58940 guidelines [9] [10] [11] [12] [13] gave essentially identical results with Mueller-Hinton and Iso-Sensitest medium, with microdilution and with agar dilution. Tables I and II list the major microorganism groups that were tested and the in-vitro activities of the seven drugs tested. No significant differences were found in the overall in-vitro activity of the old macrolide/new macrolide group (OM/NM: erythromycin, clarithromycin, roxithromycin and azithromycin) (Table I ) and the comparable resistance of these to erythromycin (Table II) confirms earlier reports. 17 Of the macrolides tested, only azithromycin demonstrated significant activity against Gram-negative strains, with 100% inhibition at MICs of 0.06-4 mg/L for all 102 Haemophilus strains tested (Table I) . Roxithromycin and the older macrolides, such as erythromycin or josamycin, were less active than azithromycin against these strains, as shown in Table I . Therefore, within the macrolide group of antibiotics only azithromycin can be recommended for use against Haemophilus spp. on the basis of in-vitro susceptibility testing. As only a few Haemophilus strains with an MIC of 8 mg/mL and no isolates with MICs of 8 mg/mL were available, no recommendations for a MIC breakpoint of resistance can be given.
Significant inhibition of methicillin-resistant staphylococci was only seen with clindamycin and the 16-membered ring antibiotics josamycin and midekamycin ( Figure 1 , Table II ). Almost 80% of the methicillin-resistant S. haemolyticus strains showed a MIC of 4 mg/L; for the OM/NM group only about 57% of strains had MICs in this range.
Although more than 400 isolates have been tested for individual comparison of special groups either not enough strains were available or the MICs were not sufficiently evenly distributed for appropriate regression analysis. Therefore, regression was performed according to DIN 58940 guidelines without extreme values (for examples see Table III Figure 1 ). The breakpoints were also determined according to the Metzler-DeHaan method. Table III clearly demonstrates that there are discrepancies when performing both calculations, but that the discrepancies are minor. It can also be seen that the calculation of breakpoints for susceptibility disc testing from regression analysis alone is not sufficient, even when the correlation coefficient is above 0.9. By applying the error-rate-bounded Metzler-DeHaan method the individual breakpoints may be adjusted with a lower margin of error. However, as can be seen with this heterogeneous mixture of strains with different phenotypic and clonal properties, more reliable and discriminative statistical methods are required to categorize in-vitro susceptibility and predict in-vivo activity. Although individual differences, preferences and pharmacokinetic profiles for the different macrolide/ lincosamide antibiotics exist, 7 according to the in-vitro data obtained and their common functional activities and resistance mechanisms, 6, 18, 19 unique breakpoints for Grampositive microorganisms may be recommended when testing according to the DIN 58940 guidelines (Table IV) . Because of the use of different inoculum densities in the DIN method, the IZD breakpoints may differ from the NCCLS 8 recommendations, with 13 mm for resistant and 18 mm for susceptible, but are similar to the recommendations of the French Society for Antimicrobial Chemotherapy. 20 The suggested DIN breakpoints should be considered tentative until verified by a larger set of bacterial isolates in collaborative studies such as those presented by the National Committee for Clinical Laboratory Standards. 
